Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Advertising Studies Move Forward Along Several Broad Fronts

You may also be interested in...



The Drug Olympics: FDA To Test Consumer Comprehension Of Composite Endpoints

FDA will explain to study participants that just as a decathlon athlete may not win at the long jump, the shot put, or the 50-yard dash but may still be the best overall, a composite score in a clinical trial may not guarantee a drug’s efficacy against any given symptom that is a component of the whole.

DTC Comparative Ads Will Likely Bloom; FDA Studies How To Evaluate New Species

FDA expects to see an increase in direct-to-consumer drug comparison ads after the Agency for Healthcare Research and Quality completes its comparative effectiveness compendium.

Lies, Damn Lies, And DTC Ads?

FDA's Risk Communications Advisory Committee is set to discuss how quantitative risk information can be presented in such a way as to inform rather than mislead consumers.

Related Content

Topics

UsernamePublicRestriction

Register

PS053351

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel